Novartis acquires Sironax’s blood-brain barrier delivery platform for $125 million
September 17, 2026
Source: drugdu
34
On September 16, Novartis announced the acquisition of biotechnology company Sironax for $125 million, gaining access to its proprietary blood-brain barrier (BBB) delivery platform technology.
Sironax's platform utilizes receptor-mediated transcytosis to efficiently deliver large molecule drugs (such as antibodies and gene therapies) into the central nervous system, addressing the longstanding challenge of large molecules being unable to cross the BBB.
The technology platform is expected to significantly enhance Novartis' drug development capabilities in central nervous system diseases, including Alzheimer's disease, Parkinson's disease, and neuro-oncology.
This acquisition continues Novartis' recent strategic investments in neuroscience and rare diseases. Blood-brain barrier delivery technology is considered a key enabling technology for next-generation CNS drug development.
Source: https://tldrbio.tech/
By editor
Copyright©2026 Ddu. All rights reserved.
Read more on
- IASO Bio’s in vivo CAR-T IASO208 receives FDA clinical trial clearance September 17, 2026
- NMPA accepts marketing registration application for Velsipity domestic manufacturing transfer September 17, 2026
- Ziprasidone mesylate from SSY Group has been approved for registration as an active pharmaceutical ingredient. September 17, 2026
- Kanghong Pharmaceutical’s research on Shugan Jieyu Capsules won the first prize of the Science and Technology Award of the Chinese Pharmaceutical Association. September 17, 2026
- Johnson & Johnson celebrates the launch of Rybrevant FASPRO (amivantamab subcutaneous injection) in China September 17, 2026
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
